This precision-focused approach aligns with PlexusDx's commitment to personalized GLP-1 therapy, ensuring your provider has both genetic and clinical data to optimize your treatment plan
It is therefore in this context, where treatment options for obesity remain very limited, that the appearance of Ozempic and Mounjaro on the market is currently generating enormous interest, both in the medical and scientific communities and in the general population
Although numerous biological targets are under investigation, most potential agents have not shown strong efficacy in late-phase clinical trial [6]
GLP-1 is a peptide in the body that helps to curb hunger and make you feel full, said Dr
Lephart have no conflicts of interest to declare
OSA approval: Zepbound became the first GLP-1 drug approved for obstructive sleep apnea in December 2025